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Résumé en
anglais
Recent studies reported cardioprotective effects of erythropoietin (EPO) against
ischemia–reperfusion (I/R) injury through activation of the reperfusion injury salvage
kinase (RISK) pathway. As RISK has been reported to be impaired in diabetes and
insulin resistance syndrome, we examined whether EPO-induced cardioprotection
was maintained in rat models of type 1 diabetes and insulin resistance syndrome.
Isolated hearts were obtained from three rat cohorts: healthy controls,
streptozotocin (STZ)-induced diabetes, and high-fat diet (HFD)-induced insulin
resistance syndrome. All hearts underwent 25 min ischemia and 30 min or 120 min
reperfusion. They were assigned to receive either no intervention or a single dose of
EPO at the onset of reperfusion. In hearts from healthy controls, EPO decreased
infarct size (14.36 ± 0.60 and 36.22 ± 4.20% of left ventricle in EPO-treated and
untreated hearts, respectively, p < 0.05) and increased phosphorylated forms of Akt,
ERK1/2, and their downstream target GSK-3β. In hearts from STZ-induced diabetic
rats, EPO did not decrease infarct size (32.05 ± 2.38 and 31.88 ± 1.87% in EPO-
treated and untreated diabetic rat hearts, respectively, NS) nor did it increase
phosphorylation of Akt, ERK1/2, and GSK-3β. In contrast, in hearts from HFD-
induced insulin resistance rats, EPO decreased infarct size (18.66 ± 1.99 and 34.62
± 3.41% in EPO-treated and untreated HFD rat hearts, respectively, p < 0.05) and
increased phosphorylation of Akt, ERK1/2, and GSK-3β. Administration of GSK-3β
inhibitor SB216763 was cardioprotective in healthy and diabetic hearts. STZ-induced
diabetes abolished EPO-induced cardioprotection against I/R injury through a
disruption of upstream signaling of GSK-3β. In conclusion, direct inhibition of
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